A Phase 4 interventional study of Ranibizumab in Neovascular Age-related Macular Degeneration, sponsored by Novartis Pharmaceuticals. Completed at 23 sites in China. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2019-09-04.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 125 studies testing ranibizumab in Macular Degeneration — 3 open to participants now, 6 under way, 4 of them phase 3. Ranibizumab · Macular Degeneration.
Among the 125 studies testing ranibizumab in Macular Degeneration, this one is the 25th largest by enrollment of the 124 interventional ones that give a count, is one of 9 that started in 2013, is one of 33 in phase 4, and was the 73rd registered.
1,459 studies on the registry are indexed under Macular Degeneration; 236 are open to participants now.
Browse Macular Degeneration studies →3 of the 125 studies testing ranibizumab in Macular Degeneration are open now, in 12 countries. Recruiting first, the newest first:
Hoffmann-La Roche · Sites in Austria, Czechia, Denmark and 10 more countries
Ages 50+
AO GENERIUM · Sites in Russian Federation
Ages 50+
AbbVie · Sites in United States
By country, each count listing its studies:
Ranibizumab: first FDA approval 2006 (LUCENTIS), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →
Of the 165 Macular Degeneration studies recruiting now, 116 (70%) set no upper age limit and 5 (3%) stop at 75 or younger; 19 take children under 18; 35 take healthy volunteers.
This study: 50 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
125 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 21 · Phase 2 43 · Phase 3 35 · Phase 4 33
First in 2002; this study’s year is marked. 9 started in 2013.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 332 is above the median of 56 across 985 interventional studies indexed under Macular Degeneration.
Median enrollment 64 across the 124 interventional studies. Of the 98 that completed or were terminated, 42 (43%) have results posted.
This tab as a report to print or save as PDF → With an account.
58 of 125 have an industry lead sponsor. The 10 most frequent:
This study is registered under Novartis Pharmaceuticals, one of the names counted as Novartis. Under that name alone:
Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.
Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
81 studies in Macular Degeneration by Novartis: 1 open now, 1 under way, none of them phase 3. Of 79 finished, 41 (52%) have results posted.
Among the 81 studies in Macular Degeneration by Novartis, this one is the 12th largest by enrollment of the 56 interventional ones that give a count, is one of 9 that started in 2013, is one of 18 in phase 4, and was the 25th registered.
Novartis’s Macular Degeneration studies by the year they started, since 2003.
3 of the studies testing ranibizumab in Macular Degeneration that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04657289Phase 3Hoffmann-La RocheA Study of the Efficacy, Safety, and Pharmacokinetics of a 36-Week Refill Regimen for the Port Delivery System With Ranibizumab in Patients With Neovascular Age-Related Macular Degeneration (Velodrome) | 2027-02-04 |
| NCT05562947Phase 3Hoffmann-La RocheA Study of the Efficacy, Safety, and Pharmacokinetics (PK) of the Port Delivery System With Ranibizumab (PDS) in Chinese Participants With Neovascular Age-related Macular Degeneration (nAMD) | 2027-06-30 |
| NCT04853251Genentech, Inc.A Study Assessing Corneal Endothelial Cells in Participants With Neovascular Age-related Macular Degeneration (nAMD) Treated With the Port Delivery System With Ranibizumab (PDS) | 2027-07-30 |
Add all 3 to your calendar (.ics) → With an account.
Among the 125 studies testing ranibizumab in Macular Degeneration, from their registry updates:
Among Novartis’s 81 in Macular Degeneration:
This tab as a report to print or save as PDF → With an account.
The study evaluated the efficacy and safety of two different dosing regimens of ranibizumab (either monthly injections or injections as-needed based on the stability of a patient's vision) in Chinese patients with wet age-related macular degeneration (AMD) . This study was to provide long-term safety data in the treatment of Chinese patients with wet AMD.
Key Inclusion criteria:
Monthly intravitreal injections of ranibizumab 0.5 mg in the core treatment period and PRN intravitreal injections of the same dose guided by best-corrected visual acuity (BCVA) stabilization in the extension treatment period
Drug: Ranibizumab
PRN intravitreal injections of ranibizumab 0.5 mg guided by best-corrected visual acuity (BCVA) stabilization in the 23 month treatment period
Drug: Ranibizumab
Intravitreal injections of 0.5 mg Ranibizumab
Average Change in Visual Acuity (Letters) From Month 3 to Month 4 Through Month 12
Visual acuity (VA) was assessed at every study visit using best correction determined from protocol refraction. VA measurements (number of letters correctly identified) were performed with the patient in a sitting position using Early Treatment Diabetic Retinopathy Study (ETDRS)-like VA testing charts at a testing distance of 4 meters. This outcome measure describes the difference between the VA averaged across all visits from Month 4 through 12 and the Month 3 Level of Visual Acuity (Letters) of the Study Eye. The treatment regimen up to Month 3 is the same in both treatment groups.
Time frame: Month 3 to month 4 through Month 12
Average Visual Acuity Change (Letters) From Month 3 to Month 4 Through Month 24
Visual acuity (VA) was assessed at every study visit using best correction determined from protocol refraction. VA measurements (number of letters correctly identified) were performed with the patient in a sitting position using Early Treatment Diabetic Retinopathy Study (ETDRS)-like visual acuity testing charts at a testing distance of 4 meters. This outcome measure describes the difference between the average level of VA over all monthly post-baseline assessments from Month 4 to Month 24 and the Month 3 Level of VA. The treatment regimen up to Month 3 is the same in both treatment groups.
Time frame: Month 3 to month 4 through Month 24
Average Visual Acuity Change From Baseline to Month 1 Through Month 12 and Month 1 Through Month 24
Visual acuity (VA) was assessed at every study visit using best correction determined from protocol refraction. VA measurements (number of letters correctly identified) were performed with the patient in a sitting position using Early Treatment Diabetic Retinopathy Study (ETDRS)-like visual acuity testing charts at a testing distance of 4 meters. This outcome measure describes the difference between VA averaged across all visits from Month 1 through Month 12 (24) and the baseline VA level
Time frame: Baseline to Month 24
Change From Baseline in Visual Acuity (Letters) of the Study Eye Over Time
Visual acuity (VA) was assessed on both eyes during every study visit using best correction determined from protocol refraction. VA measurements (number of letters correctly identified) were performed with the patient in a sitting position using Early Treatment Diabetic Retinopathy Study (ETDRS)-like visual acuity testing charts at a testing distance of 4 meters. This outcome measure describes the change in visual acuity at each visit compared to baseline
Time frame: Baseline to 24 months
Number of Patients With a BCVA Improvement of ≥5, ≥10, ≥15, and ≥30 Letters From Baseline to Month 24
Visual acuity (VA) was at every study visit using best correction determined from protocol refraction. VA measurements (number of letters correctly identified) were performed with the patient in a sitting position using Early Treatment Diabetic Retinopathy Study (ETDRS)-like visual acuity testing charts at a testing distance of 4 meters. This outcome measure describes for each post-baseline month whether or not a patient improved by equal or more than 5, 10, 15,or 30 letters of VA as compared to baseline.
Time frame: Baseline to Month 24
Number of Patients With a BCVA Loss of 15 Letters in the Study Eye Over Time
Visual acuity (VA) was assessed at every study visit using best correction determined from protocol refraction. VA measurements (number of letters correctly identified) were performed with the patient in a sitting position using Early Treatment Diabetic Retinopathy Study (ETDRS)-like visual acuity testing charts at a testing distance of 4 meters. This outcome measure describes for each post-baseline month whether or not a patient lost less than 15 letters of VA as compared with baseline.
Time frame: Baseline to Month 24
Number of Patients With a Best Corrected Visual Acuity (BCVA) of More of 73 Letters or More
Visual acuity (VA) was assessed at every study visit using best correction determined from protocol refraction. VA measurements (number of letters correctly identified) were performed with the patient in a sitting position using Early Treatment Diabetic Retinopathy Study (ETDRS)-like visual acuity testing charts at a testing distance of 4 meters. This outcome measure describes for Month 12 and Month 24 whether a patient had a VA score of 73 or more letters
Time frame: Month 12 and 24
Change From Baseline in Central Sub-Field Thickness (CSFT) of the Study Eye Over Time to Month 12 and Month 24
Optical coherence tomography(OCT) was used to assess CSFT (Central Sub-Field Thickness) representing the average retinal thickness of the circular area within 1 mm diameter around the foveal center. The Ns in the rows is the number of patients with a value for both baseline and the specific post-baseline visit
Time frame: Baseline to Month 24
Duration of Ranibizumab Treatment Free Interval in the Study Eye up to Month 24
This outcome measure describes duration of treatment-free intervals. Treatment-free interval is defined as the number of visits (whether attended or not) where ranibizumab was not administered. n= the number of patients who had at least one ranibizumab treatment interruption
Time frame: up to month 24
Duration of Ranibizumab Treatment Free Interval in the Study Eye Prior to Month 12
This outcome measure describes duration of treatment-free intervals prior to month 12. Treatment-free interval is defined as the number of visits (whether attended or not) where ranibizumab was not administered. n= the number of patients who had at least one ranibizumab treatment interruption Treatment-free interval is analyzed in the Ranibizumab 0.5 mg PRN group only. It is not analyzed in the Ranibizumab 0.5 mg monthly group because, by protocol design, these participants receive treatment monthly. Therefore, the analysis does not apply to this group.
Time frame: prior to month 12
Duration of Active Treatment Phase Prior to Month 12
Time frame: Prior to month 12
Duration of Active Treatment Phase up to Month 24
Time frame: up to month 24
| Milestone | Ranibizumab 0.5 mg Monthly | Ranibizumab 0.5 mg PRN |
|---|---|---|
| Started | 168 | 166 |
| Full analysis set | 167 | 166 |
| Per protocol set | 157 | 155 |
| Safety set | 166 | 166 |
| Completed | 157 | 156 |
| Not completed | 11 | 10 |
| Withdrew: Disease progression | 0 | 1 |
| Withdrew: Physician decision | 1 | 1 |
| Withdrew: Death | 0 | 1 |
| Withdrew: Administrative problems | 1 | 0 |
| Withdrew: Withdrawal by subject | 4 | 2 |
| Withdrew: Adverse event | 5 | 5 |
| Milestone | Ranibizumab 0.5 mg Monthly | Ranibizumab 0.5 mg PRN |
|---|---|---|
| Started | 157 | 156 |
| Completed | 145 | 138 |
| Not completed | 12 | 18 |
| Withdrew: Adverse event | 3 | 2 |
| Withdrew: Physician decision | 0 | 2 |
| Withdrew: Administrative problems | 0 | 1 |
| Withdrew: Lost to follow-up | 0 | 1 |
| Withdrew: Withdrawal by subject | 9 | 12 |
Visual acuity (VA) was assessed at every study visit using best correction determined from protocol refraction. VA measurements (number of letters correctly identified) were performed with the patient in a sitting position using Early Treatment Diabetic Retinopathy Study (ETDRS)-like VA testing charts at a testing distance of 4 meters. This outcome measure describes the difference between the VA averaged across all visits from Month 4 through 12 and the Month 3 Level of Visual Acuity (Letters) of the Study Eye. The treatment regimen up to Month 3 is the same in both treatment groups.
| Letters | Ranibizumab 0.5 mg Monthly | Ranibizumab 0.5 mg PRN |
|---|---|---|
| Average Change in Visual Acuity (Letters) From Month 3 to Month 4 Through Month 12 | 3.3 ± 5.61 | 1.7 ± 6.87 |
Visual acuity (VA) was assessed at every study visit using best correction determined from protocol refraction. VA measurements (number of letters correctly identified) were performed with the patient in a sitting position using Early Treatment Diabetic Retinopathy Study (ETDRS)-like visual acuity testing charts at a testing distance of 4 meters. This outcome measure describes the difference between the average level of VA over all monthly post-baseline assessments from Month 4 to Month 24 and the Month 3 Level of VA. The treatment regimen up to Month 3 is the same in both treatment groups.
| Letters | Ranibizumab 0.5 mg Monthly | Ranibizumab 0.5 mg PRN |
|---|---|---|
| Average Visual Acuity Change (Letters) From Month 3 to Month 4 Through Month 24 | 3.7 ± 7.36 | 2.2 ± 7.95 |
Visual acuity (VA) was assessed at every study visit using best correction determined from protocol refraction. VA measurements (number of letters correctly identified) were performed with the patient in a sitting position using Early Treatment Diabetic Retinopathy Study (ETDRS)-like visual acuity testing charts at a testing distance of 4 meters. This outcome measure describes the difference between VA averaged across all visits from Month 1 through Month 12 (24) and the baseline VA level
| Letters | Ranibizumab 0.5 mg Monthly | Ranibizumab 0.5 mg PRN |
|---|---|---|
| Average Month 1 through month 12 | 10.1 ± 9.37 | 8.1 ± 10.95 |
| Average Month 1 through month 24 | 11.0 ± 10.28 | 8.9 ± 11.95 |
Visual acuity (VA) was assessed on both eyes during every study visit using best correction determined from protocol refraction. VA measurements (number of letters correctly identified) were performed with the patient in a sitting position using Early Treatment Diabetic Retinopathy Study (ETDRS)-like visual acuity testing charts at a testing distance of 4 meters. This outcome measure describes the change in visual acuity at each visit compared to baseline
| letters | Ranibizumab 0.5 mg Monthly | Ranibizumab 0.5 mg PRN |
|---|---|---|
| Month 1 | 4.3 ± 6.75 | 3.4 ± 8.74 |
| Month 2 | 6.8 ± 8.02 | 6.3 ± 9.94 |
| Month 3 | 8.0 ± 9.38 | 7.2 ± 11.48 |
| Month 4 | 9.3 ± 10.52 | 7.9 ± 11.67 |
| Month 5 | 9.9 ± 10.71 | 8.4 ± 11.66 |
| Month 6 | 10.7 ± 10.92 | 8.7 ± 12.33 |
| Month 7 | 11.4 ± 10.49 | 8.5 ± 13.01 |
| Month 8 | 11.3 ± 11.06 | 8.8 ± 12.53 |
| Month 9 | 11.8 ± 10.90 | 9.2 ± 12.83 |
| Month 10 | 12.4 ± 11.24 | 9.4 ± 12.84 |
| Month 11 | 12.5 ± 10.90 | 9.6 ± 12.89 |
| Month 12 | 12.3 ± 11.47 | 9.6 ± 13.06 |
| Month 13 | 12.2 ± 12.04 | 9.9 ± 12.98 |
| Month 14 | 12.1 ± 12.18 | 10.0 ± 13.29 |
| Month 15 | 12.2 ± 12.19 | 9.9 ± 13.56 |
| Month 16 | 12.3 ± 11.59 | 10.0 ± 13.64 |
| Month 17 | 12.1 ± 11.94 | 10.4 ± 13.78 |
| Month 18 | 11.8 ± 12.31 | 10.1 ± 13.25 |
| Month 19 | 12.1 ± 12.43 | 9.8 ± 14.54 |
| Month 20 | 12.1 ± 12.70 | 9.8 ± 14.74 |
| Month 21 | 11.9 ± 13.17 | 9.6 ± 14.73 |
| Month 22 | 11.3 ± 13.19 | 9.5 ± 15.26 |
| Month 23 | 11.5 ± 13.23 | 9.2 ± 15.13 |
| Month 24 | 11.3 ± 13.72 | 9.3 ± 15.48 |
Visual acuity (VA) was at every study visit using best correction determined from protocol refraction. VA measurements (number of letters correctly identified) were performed with the patient in a sitting position using Early Treatment Diabetic Retinopathy Study (ETDRS)-like visual acuity testing charts at a testing distance of 4 meters. This outcome measure describes for each post-baseline month whether or not a patient improved by equal or more than 5, 10, 15,or 30 letters of VA as compared to baseline.
| Patients | Ranibizumab 0.5 mg Monthly | Ranibizumab 0.5 mg PRN |
|---|---|---|
| Month 1 Gain of >=5 letters | 75 | 65 |
| Month 1 Gain of >=10 letters | 27 | 31 |
| Month 1 Gain of >=15 letters | 11 | 17 |
| Month 1 Gain of >=30 letters | 1 | 1 |
| Month 2 Gain of >=5 letters | 98 | 95 |
| Month 2 Gain of >=10 letters | 54 | 48 |
| Month 2 Gain of >=15 letters | 28 | 32 |
| Month 2 Gain of >=30 letters | 1 | 1 |
| Month 3 Gain of >=5 letters | 107 | 100 |
| Month 3 Gain of >=10 letters | 71 | 60 |
| Month 3 Gain of >=15 letters | 40 | 37 |
| Month 3 Gain of >=30 letters | 1 | 4 |
| Month 4 Gain of >=5 letters | 115 | 100 |
| Month 4 Gain of >=10 letters | 80 | 75 |
| Month 4 Gain of >=15 letters | 53 | 46 |
| Month 4 Gain of >=30 letters | 3 | 4 |
| Month 5 Gain of >=5 letters | 114 | 109 |
| Month 5 Gain of >=10 letters | 88 | 72 |
| Month 5 Gain of >=15 letters | 59 | 46 |
| Month 5 Gain of >=30 letters | 4 | 5 |
| Month 6 Gain of >=5 letters | 124 | 108 |
| Month 6 Gain of >=10 letters | 86 | 75 |
| Month 6 Gain of >=15 letters | 60 | 44 |
| Month 6 Gain of >=30 letters | 6 | 9 |
| Month 7 Gain of >=5 letters | 127 | 114 |
| Month 7 Gain of >=10 letters | 89 | 70 |
| Month 7 Gain of >=15 letters | 63 | 50 |
| Month 7 Gain of >=30 letters | 5 | 10 |
| Month 8 Gain of >=5 letters | 129 | 110 |
| Month 8 Gain of >=10 letters | 89 | 74 |
| Month 8 Gain of >=15 letters | 66 | 54 |
| Month 8 Gain of >=30 letters | 6 | 7 |
| Month 9 Gain of >=5 letters | 126 | 107 |
| Month 9 Gain of >=10 letters | 95 | 78 |
| Month 9 Gain of >=15 letters | 69 | 57 |
| Month 9 Gain of >=30 letters | 6 | 11 |
| Month 10 Gain of >=5 letters | 128 | 116 |
| Month 10 Gain of >=10 letters | 95 | 75 |
| Month 10 Gain of >=15 letters | 74 | 53 |
| Month 10 Gain of >=30 letters | 8 | 11 |
| Month 11 Gain of >=5 letters | 130 | 115 |
| Month 11 Gain of >=10 letters | 97 | 77 |
| Month 11 Gain of >=15 letters | 78 | 56 |
| Month 11 Gain of >=30 letters | 7 | 11 |
| Month 12 Gain of >=5 letters | 129 | 114 |
| Month 12 Gain of >=10 letters | 97 | 82 |
| Month 12 Gain of >=15 letters | 69 | 52 |
| Month 12 Gain of >=30 letters | 7 | 11 |
| Month 13 Gain of >=5 letters | 127 | 118 |
| Month 13 Gain of >=10 letters | 96 | 92 |
| Month 13 Gain of >=15 letters | 67 | 56 |
| Month 13 Gain of >=30 letters | 9 | 11 |
| Month 14 Gain of >=5 letters | 124 | 117 |
| Month 14 Gain of >=10 letters | 100 | 88 |
| Month 14 Gain of >=15 letters | 70 | 65 |
| Month 14 Gain of >=30 letters | 9 | 13 |
| Month 15 Gain of >=5 letters | 126 | 112 |
| Month 15 Gain of >=10 letters | 104 | 84 |
| Month 15 Gain of >=15 letters | 68 | 62 |
| Month 15 Gain of >=30 letters | 8 | 13 |
| Month 16 Gain of >=5 letters | 126 | 114 |
| Month 16 Gain of >=10 letters | 101 | 87 |
| Month 16 Gain of >=15 letters | 71 | 62 |
| Month 16 Gain of >=30 letters | 7 | 11 |
| Month 17 Gain of >=5 letters | 119 | 116 |
| Month 17 Gain of >=10 letters | 102 | 87 |
| Month 17 Gain of >=15 letters | 71 | 62 |
| Month 17 Gain of >=30 letters | 5 | 12 |
| Month 18 Gain of >=5 letters | 121 | 117 |
| Month 18 Gain of >=10 letters | 101 | 87 |
| Month 18 Gain of >=15 letters | 69 | 61 |
| Month 18 Gain of >=30 letters | 6 | 13 |
| Month 19 Gain of >=5 letters | 121 | 115 |
| Month 19 Gain of >=10 letters | 94 | 88 |
| Month 19 Gain of >=15 letters | 75 | 62 |
| Month 19 Gain of >=30 letters | 9 | 11 |
| Month 20 Gain of >=5 letters | 116 | 116 |
| Month 20 Gain of >=10 letters | 98 | 85 |
| Month 20 Gain of >=15 letters | 72 | 63 |
| Month 20 Gain of >=30 letters | 10 | 13 |
| Month 21 Gain of >=5 letters | 120 | 117 |
| Month 21 Gain of >=10 letters | 96 | 81 |
| Month 21 Gain of >=15 letters | 76 | 61 |
| Month 21 Gain of >=30 letters | 11 | 12 |
| Month 22 Gain of >=5 letters | 116 | 114 |
| Month 22 Gain of >=10 letters | 92 | 88 |
| Month 22 Gain of >=15 letters | 69 | 64 |
| Month 22 Gain of >=30 letters | 14 | 13 |
| Month 23 Gain of >=5 letters | 119 | 115 |
| Month 23 Gain of >=10 letters | 93 | 85 |
| Month 23 Gain of >=15 letters | 72 | 62 |
| Month 23 Gain of >=30 letters | 8 | 13 |
| Month 24 Gain of >=5 letters | 114 | 116 |
| Month 24 Gain of >=10 letters | 95 | 83 |
| Month 24 Gain of >=15 letters | 73 | 60 |
| Month 24 Gain of >=30 letters | 11 | 13 |
Visual acuity (VA) was assessed at every study visit using best correction determined from protocol refraction. VA measurements (number of letters correctly identified) were performed with the patient in a sitting position using Early Treatment Diabetic Retinopathy Study (ETDRS)-like visual acuity testing charts at a testing distance of 4 meters. This outcome measure describes for each post-baseline month whether or not a patient lost less than 15 letters of VA as compared with baseline.
| Patients | Ranibizumab 0.5 mg Monthly | Ranibizumab 0.5 mg PRN |
|---|---|---|
| Month 1, Loss of < 15 letters | 164 | 163 |
| Month 2, Loss of < 15 letters | 163 | 162 |
| Month 3, Loss of < 15 letters | 160 | 162 |
| Month 4, Loss of < 15 letters | 161 | 162 |
| Month 5, Loss of < 15 letters | 160 | 160 |
| Month 6, Loss of < 15 letters | 162 | 160 |
| Month 7, Loss of < 15 letters | 162 | 158 |
| Month 8, Loss of < 15 letters | 162 | 159 |
| Month 9, Loss of < 15 letters | 163 | 159 |
| Month 10, Loss of < 15 letters | 162 | 161 |
| Month 11, Loss of < 15 letters | 162 | 161 |
| Month 12, Loss of < 15 letters | 162 | 160 |
| Month 13, Loss of < 15 letters | 162 | 157 |
| Month 14, Loss of < 15 letters | 161 | 158 |
| Month 15, Loss of < 15 letters | 162 | 159 |
| Month 16, Loss of < 15 letters | 163 | 159 |
| Month 17, Loss of < 15 letters | 161 | 157 |
| Month 18, Loss of < 15 letters | 159 | 157 |
| Month 19, Loss of < 15 letters | 162 | 155 |
| Month 20, Loss of < 15 letters | 161 | 155 |
| Month 21, Loss of < 15 letters | 157 | 155 |
| Month 22, Loss of < 15 letters | 160 | 154 |
| Month 23, Loss of < 15 letters | 158 | 153 |
| Month 24, Loss of < 15 letters | 158 | 153 |
Visual acuity (VA) was assessed at every study visit using best correction determined from protocol refraction. VA measurements (number of letters correctly identified) were performed with the patient in a sitting position using Early Treatment Diabetic Retinopathy Study (ETDRS)-like visual acuity testing charts at a testing distance of 4 meters. This outcome measure describes for Month 12 and Month 24 whether a patient had a VA score of 73 or more letters
| Patients | Ranibizumab 0.5 mg Monthly | Ranibizumab 0.5 mg PRN |
|---|---|---|
| Month 12>=73 letters | 68 | 56 |
| Month 24>=73 letters | 63 | 59 |
Optical coherence tomography(OCT) was used to assess CSFT (Central Sub-Field Thickness) representing the average retinal thickness of the circular area within 1 mm diameter around the foveal center. The Ns in the rows is the number of patients with a value for both baseline and the specific post-baseline visit
| microns | Ranibizumab 0.5 mg Monthly | Ranibizumab 0.5 mg PRN |
|---|---|---|
| Month 1 | -112.8 ± 117.95 | -108.7 ± 124.93 |
| Month 2 | -141.1 ± 126.44 | -130.4 ± 145.58 |
| Month 3 | -141.3 ± 127.47 | -141.2 ± 161.88 |
| Month 4 | -150.4 ± 131.71 | -134.5 ± 158.88 |
| Month 5 | -155.2 ± 134.58 | -131.5 ± 155.98 |
| Month 6 | -158.6 ± 135.37 | -138.3 ± 159.07 |
| Month 7 | -156.9 ± 136.61 | -137.9 ± 165.24 |
| Month 8 | -165.4 ± 135.59 | -142.2 ± 165.76 |
| Month 9 | -165.1 ± 136.04 | -143.3 ± 176.68 |
| Month 10 | -165.9 ± 136.03 | -152.5 ± 177.11 |
| Month 11 | -166.6 ± 140.62 | -152.5 ± 175.56 |
| Month 12 | -166.5 ± 143.85 | -155.7 ± 173.19 |
| Month 13 | -160.3 ± 142.02 | -151.4 ± 168.89 |
| Month 14 | -159.9 ± 144.14 | -153.2 ± 167.81 |
| Month 15 | -156.9 ± 152.33 | -158.1 ± 169.56 |
| Month 16 | -155.9 ± 154.82 | -158.1 ± 173.23 |
| Month 17 | -161.8 ± 155.18 | -156.8 ± 167.89 |
| Month 18 | -159.5 ± 159.78 | -156.7 ± 174.88 |
| Month 19 | -158.5 ± 163.82 | -154.8 ± 177.49 |
| Month 20 | -157.6 ± 161.04 | -152.1 ± 173.30 |
| Month 21 | -155.2 ± 160.03 | -151.9 ± 171.95 |
| Month 22 | -156.8 ± 161.35 | -146.5 ± 176.83 |
| Month 23 | -159.4 ± 163.58 | -148.3 ± 185.62 |
| Month 24 | -167.7 ± 163.12 | -153.2 ± 178.22 |
This outcome measure describes duration of treatment-free intervals. Treatment-free interval is defined as the number of visits (whether attended or not) where ranibizumab was not administered. n= the number of patients who had at least one ranibizumab treatment interruption
| Months | Ranibizumab 0.5 mg Monthly | Ranibizumab 0.5 mg PRN |
|---|---|---|
| First treatment free interval (n=99,144) | 2.9 ± 2.38 | 3.7 ± 4.67 |
| Second treatment free interval (n=49,112) | 2.1 ± 1.51 | 3.3 ± 3.48 |
| Third treatment free interval (n=12,78) | 1.5 ± 0.52 | 3.0 ± 2.67 |
This outcome measure describes duration of treatment-free intervals prior to month 12. Treatment-free interval is defined as the number of visits (whether attended or not) where ranibizumab was not administered. n= the number of patients who had at least one ranibizumab treatment interruption Treatment-free interval is analyzed in the Ranibizumab 0.5 mg PRN group only. It is not analyzed in the Ranibizumab 0.5 mg monthly group because, by protocol design, these participants receive treatment monthly. Therefore, the analysis does not apply to this group.
| Months | Ranibizumab 0.5 mg PRN |
|---|---|
| First treatment free interval (n=127) | 2.7 ± 2.22 |
| Second treatment free interval (n=73) | 2.0 ± 1.29 |
| Third treatment free interval (n=19) | 1.3 ± 0.67 |
| Months | Ranibizumab 0.5 mg Monthly | Ranibizumab 0.5 mg PRN |
|---|---|---|
| Duration of Active Treatment Phase Prior to Month 12 | 10.5 ± 1.86 | 9.1 ± 2.76 |
| Months | Ranibizumab 0.5 mg Monthly | Ranibizumab 0.5 mg PRN |
|---|---|---|
| Duration of Active Treatment Phase up to Month 24 | 18.0 ± 5.99 | 17.1 ± 6.90 |
Non-serious events are listed at a 1% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Ranibizumab 0.5 mg Monthly | — | 24/166 (14.5%) | 107/166 (64.5%) |
| Ranibizumab 0.5 mg PRN | — | 24/166 (14.5%) | 87/166 (52.4%) |
| Event | Ranibizumab 0.5 mg Monthly | Ranibizumab 0.5 mg PRN |
|---|---|---|
| Cerebral infarctionNervous system disorders | 4/166 | 1/166 |
| Angina pectorisCardiac disorders | 2/166 | 0/166 |
| Coronary artery diseaseCardiac disorders | 2/166 | 1/166 |
| Vitreous haemorrhageEye disorders | 0/166 | 2/166 |
| Lacunar infarctionNervous system disorders | 0/166 | 2/166 |
| Acute myocardial infarctionCardiac disorders | 0/166 | 1/166 |
| Angina unstableCardiac disorders | 1/166 | 0/166 |
| Atrial fibrillationCardiac disorders | 0/166 | 1/166 |
| Cardiac discomfortCardiac disorders | 0/166 | 1/166 |
| Cardiac failureCardiac disorders | 0/166 | 1/166 |
| Event | Ranibizumab 0.5 mg Monthly | Ranibizumab 0.5 mg PRN |
|---|---|---|
| NasopharyngitisInfections and infestations | 24/166 | 18/166 |
| Conjunctival haemorrhageEye disorders | 21/166 | 12/166 |
| Upper respiratory tract infectionInfections and infestations | 14/166 | 7/166 |
| Intraocular pressure increasedInvestigations | 5/166 | 12/166 |
| Blood glucose increasedInvestigations | 10/166 | 5/166 |
| CoughRespiratory, thoracic and mediastinal disorders | 8/166 | 7/166 |
| HypertensionVascular disorders | 8/166 | 8/166 |
| Visual acuity reducedEye disorders | 7/166 | 2/166 |
| DizzinessNervous system disorders | 5/166 | 7/166 |
| Retinal haemorrhageEye disorders | 5/166 | 6/166 |
| Age, Continuous(Years) | Ranibizumab 0.5 mg Monthly | Ranibizumab 0.5 mg PRN | Total |
|---|---|---|---|
| Mean | 65.6 ± 8.43 | 66.8 ± 8.31 | 66.2 ± 8.38 |
| Sex: Female, Male(Participants) | Ranibizumab 0.5 mg Monthly | Ranibizumab 0.5 mg PRN | Total |
|---|---|---|---|
| Female | 48 | 47 | 95 |
| Male | 119 | 119 | 238 |
Ran from Feb 2013 to primary completion in Nov 2015, 33 months.
Results were first posted in Feb 2018, 2 years 2 months after primary completion.
Of 24 industry-sponsored phase 4 interventional studies under Macular Degeneration, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 36. This study's 33 months is above that.
Counting every sponsor, half of 45 studies reached it within 26 months; a quarter within 14 and three quarters within 39.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ranibizumab